Novartis announced that Vanrafia (atrasentan) significantly slowed kidney function decline by approximately 34% compared to placebo over 2.5 years in adults with IgA nephropathy, based on Phase III ALIGN study results published in The Lancet. The drug also reduced proteinuria by over 38% at 9 months, with sustained benefits through treatment end. Patients on background SGLT2 inhibitors also showed consistent kidney function preservation. Vanrafia, already approved in the U.S. and China for proteinuria reduction in IgAN, is positioned as a foundational therapy to address this progressive kidney disease, with Novartis planning submissions for traditional approval in 2026.
Novartis will showcase results from multiple clinical trials of Rhapsido (remibrutinib) at the EAACI Congress 2026, including pivotal Phase III data for chronic inducible urticaria and extension data for chronic spontaneous urticaria. The presentatio...
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
Novartis announced that its drug Cosentyx (secukinumab) demonstrated statistically significant and clinically meaningful sustained remission in patients with polymyalgia rheumatica (PMR) compared to placebo, according to Phase III REPLENISH trial dat...
